What are the oral hypoglycemics that should be avoided in ckd with cut

What are the oral hypoglycemics that should be avoided in ckd with cutoffs

Reading File

Finding Sources

Searching the Web

oral hypoglycemic agents to avoid in CKD eGFR cutoffs 2024

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I now have a comprehensive, textbook-sourced table. Let me compile the full answer.

Here is a detailed breakdown of oral hypoglycemic agents (OHAs) to avoid or dose-adjust in CKD, based on the table from Comprehensive Clinical Nephrology, 7th Edition (Table 33.1) and supplemented by current consensus guidelines.

Oral Hypoglycemics to Avoid or Restrict in CKD - eGFR Cutoffs

1. Biguanides (Metformin)

Drug	Cutoff	Action
Metformin IR	eGFR 30-44	Reduce to 850-1000 mg once daily
Metformin IR/ER	eGFR <30 (CKD 4-5)	Avoid - risk of lactic acidosis
Metformin ER	eGFR 30-44	Reduce to 1000 mg once daily

Key concern: lactic acidosis from accumulation
Also hold temporarily during acute illness, contrast dye, surgery

2. Sulfonylureas (SUs)

Drug	Cutoff	Action
Glibenclamide / Glyburide	eGFR <60	Avoid - active metabolites accumulate, severe hypoglycemia risk
Glimepiride	eGFR <60	Avoid - active metabolites accumulate
Tolbutamide	Any CKD	Avoid - not recommended
Gliclazide	eGFR <15 (CKD5)	Avoid; safe at lower doses in CKD3-4 (40 mg/day)
Glipizide	No dose adjustment needed	Safest SU in CKD - inactive metabolites

The key distinction: glipizide is the SU of choice in CKD because its metabolites are inactive and not renally cleared
Glibenclamide, glimepiride, and tolbutamide are the ones most strongly to avoid

3. SGLT-2 Inhibitors (also useful in CKD, but efficacy drops at low eGFR)

Drug	Cutoff	Action
Canagliflozin	eGFR <30 (CKD4-5)	Avoid initiation; if already on, can continue
Dapagliflozin	eGFR <25	Avoid initiation
Empagliflozin	eGFR <20	Avoid initiation

Note: At eGFR <45, glycemic efficacy is minimal, but cardio/renoprotective benefits persist - so SGLT2i are not just "avoided" in CKD but often continued for non-glycemic reasons

4. GLP-1 Receptor Agonists

Drug	Cutoff	Action
Exenatide IR	eGFR <30	Avoid - renal clearance, GI side effects worsen dehydration/AKI risk
Exenatide ER	eGFR <45 (CKD3b)	Avoid
Dulaglutide	eGFR <15	Avoid (limited data); usable up to CKD4
Semaglutide, Liraglutide	eGFR <15	Limited experience; use with caution

5. DPP-4 Inhibitors (Gliptins)

Drug	Cutoff	Action
Sitagliptin	eGFR 30-44 → 50 mg/day; eGFR <30 → 25 mg/day	Dose reduce, do NOT avoid
Saxagliptin	eGFR <45 → 2.5 mg/day	Dose reduce; also avoid in dialysis patients (increased HHF risk)
Linagliptin	No adjustment at any stage	Safest gliptin - entirely biliary excretion
Alogliptin	eGFR 30-59 → 12.5 mg/day; eGFR <30 → 6.25 mg/day	Dose reduce

6. Thiazolidinediones (TZDs)

Drug	Cutoff	Action
Pioglitazone	No dose adjustment	Can be used in all CKD stages; however, avoid in fluid-overloaded patients (causes Na/water retention and worsens edema)

7. Meglitinides (Glinides)

Drug	Cutoff	Action
Repaglinide	Use with caution eGFR <30; start at 0.5 mg	Generally safe until eGFR <30
Nateglinide	eGFR <30	Avoid - active metabolites accumulate renally

8. Alpha-Glucosidase Inhibitors

Drug	Cutoff	Action
Acarbose	sCr >2.0 mg/dL	Avoid - not recommended with significant renal impairment
Voglibose	No dose adjustment generally required	Less concern

Quick Summary: "Avoid" List by eGFR

eGFR Threshold	Drugs to Avoid
<60	Glibenclamide/Glyburide, Glimepiride
<45	Exenatide ER
<30	Metformin, Exenatide IR, Nateglinide, Canagliflozin (initiation)
<25	Dapagliflozin (initiation)
<20	Empagliflozin (initiation)
sCr >2 mg/dL	Acarbose

Key teaching points:

Safest agents in advanced CKD: Linagliptin, Pioglitazone, Insulin (titrate doses down)
Preferred SU if needed: Glipizide (no dose adjustment, inactive metabolites)
Most dangerous SU in CKD: Glyburide/Glibenclamide (accumulates, severe prolonged hypoglycemia)
Metformin: Avoid at eGFR <30; the KDIGO 2022 and ADA guidelines allow reduced doses down to eGFR 30, with dose reduction starting at eGFR <45

Sources: Comprehensive Clinical Nephrology, 7th Edition, Table 33.1; KDIGO 2022 Diabetes in CKD Guideline; ADA/KDIGO Consensus 2022

This is a shared conversation. Sign in to Orris to start your own chat.